THE IMPACT OF HAEMATOLOGICAL MALIGNANCY ON PATIENTS’ HEALTH-RELATED QUALITY OF LIFE AND SYMPTOMS: A QUALITATIVE STUDY
(Abstract release date: 05/19/16)
EHA Library. Salek S. 06/09/16; 132996; E1447
Prof. Dr. Sam Salek
Contributions
Contributions
Abstract
Abstract: E1447
Type: Eposter Presentation
Background
The impact of haematological malignancies (HM) in patients' lives is not well understood. For some there is a possibility of cure, for others treatment aims at prolonging survival or containing symptoms and complications. We present interim results of a cross-sectional qualitative study in patients with HM.
Aims
The aim of this study was to investigate the impact of a wide range of haematological malignancies and their treatments on patients’ health-related quality of life (HRQoL) and Symptoms.
Methods
Multicentre Ethics approval was obtained from the NRES South West Bristols, UK. Adult patients with HM as per 2008 WHO classification, capable of reading English and able to give the written informed consent were recruited from inpatient/outpatient clinics of two secondary care hospitals in England and Wales. This qualitative study employed semi-structured face-to-face interviews with open-ended questions related to HRQoL and symptoms. All the interviews were audio recorded and transcribed verbatim and content analysis was carried out using the NVivo 11 qualitative analysis software.
Results
Fifty-five patients (male=27; mean age = 60 years; SD=15.2; median age 63 years; and age range =21-83 years) with mean duration of the HM of 3.8 years (SD=4.7; median=2.1 years; and range= 19 days-23 years) were recruited into the study. Diagnoses were Acute Myeloid Leukaemia (11), Acute Lymphoid Leukaemia (3), Chronic Myeloid Leukaemia (6), Chronic Lymphoid Leukaemia (4), Aggressive Non-Hodgkin’s Lymphoma (3), Indolent Non-Hodgkin’s Lymphoma (7), Hodgkin’s Lymphoma (3), Multiple Myeloma (12), Myeloproliferative Neoplasm (3) and Myelodysplastic Syndrome (3). There were overall 44 categories of issues identified which were important from the patient perspective. These issues were then divided into two broad categories: QoL and symptoms. The QoL issues which had the highest impact on patients’ lives (Figure1) were: ‘social life and participatory function; going on holidays and travelling; physical functioning or independency; sleeping patterns; eating and drinking habits; work life; and sexual life’ from high to low prevalence, respectively. Forty-four percent of the patients experienced impairment in different aspects of their work life with the prevalence of sixty-two percent (4 job role function; 2 made redundant; 3 relationship with co-workers; and 24 overall work life). Most of the patients who suffered from financial difficulties because of their HM were from 35-65 age group. With respect to disease related symptoms, 62 issues were identified, the most prevalent being ‘tiredness (35%), feeling unwell (24%), breathlessness (23%), lack of energy (16%), back pain (15%) and weight loss (13%)', from high to low prevalence respectively. Out of 78 treatment related symptoms identified, the most prevalent symptoms were ‘tiredness (36%), feeling sick (17%), breathlessness (14%), loss of appetite (9%), neutropenia related symptoms such as infections & slowed healing (8%), nausea (8%) and lack of energy (8%)’, from high to low prevalence, respectively.
Conclusion
The findings of this study clearly indicate that haematological patients’ lives are greatly affected by their disease and treatment. This highlights the need for development of a new measure of HRQoL and symptoms, specific for the assessment of patients with HM to evaluate individual intervention strategies in daily clinical practice. This could lead to greater patient engagement in the process of clinical decision-making.
Session topic: E-poster
Keyword(s): Hematological malignancy, Outcome measurement, Quality of life
Type: Eposter Presentation
Background
The impact of haematological malignancies (HM) in patients' lives is not well understood. For some there is a possibility of cure, for others treatment aims at prolonging survival or containing symptoms and complications. We present interim results of a cross-sectional qualitative study in patients with HM.
Aims
The aim of this study was to investigate the impact of a wide range of haematological malignancies and their treatments on patients’ health-related quality of life (HRQoL) and Symptoms.
Methods
Multicentre Ethics approval was obtained from the NRES South West Bristols, UK. Adult patients with HM as per 2008 WHO classification, capable of reading English and able to give the written informed consent were recruited from inpatient/outpatient clinics of two secondary care hospitals in England and Wales. This qualitative study employed semi-structured face-to-face interviews with open-ended questions related to HRQoL and symptoms. All the interviews were audio recorded and transcribed verbatim and content analysis was carried out using the NVivo 11 qualitative analysis software.
Results
Fifty-five patients (male=27; mean age = 60 years; SD=15.2; median age 63 years; and age range =21-83 years) with mean duration of the HM of 3.8 years (SD=4.7; median=2.1 years; and range= 19 days-23 years) were recruited into the study. Diagnoses were Acute Myeloid Leukaemia (11), Acute Lymphoid Leukaemia (3), Chronic Myeloid Leukaemia (6), Chronic Lymphoid Leukaemia (4), Aggressive Non-Hodgkin’s Lymphoma (3), Indolent Non-Hodgkin’s Lymphoma (7), Hodgkin’s Lymphoma (3), Multiple Myeloma (12), Myeloproliferative Neoplasm (3) and Myelodysplastic Syndrome (3). There were overall 44 categories of issues identified which were important from the patient perspective. These issues were then divided into two broad categories: QoL and symptoms. The QoL issues which had the highest impact on patients’ lives (Figure1) were: ‘social life and participatory function; going on holidays and travelling; physical functioning or independency; sleeping patterns; eating and drinking habits; work life; and sexual life’ from high to low prevalence, respectively. Forty-four percent of the patients experienced impairment in different aspects of their work life with the prevalence of sixty-two percent (4 job role function; 2 made redundant; 3 relationship with co-workers; and 24 overall work life). Most of the patients who suffered from financial difficulties because of their HM were from 35-65 age group. With respect to disease related symptoms, 62 issues were identified, the most prevalent being ‘tiredness (35%), feeling unwell (24%), breathlessness (23%), lack of energy (16%), back pain (15%) and weight loss (13%)', from high to low prevalence respectively. Out of 78 treatment related symptoms identified, the most prevalent symptoms were ‘tiredness (36%), feeling sick (17%), breathlessness (14%), loss of appetite (9%), neutropenia related symptoms such as infections & slowed healing (8%), nausea (8%) and lack of energy (8%)’, from high to low prevalence, respectively.
Conclusion
The findings of this study clearly indicate that haematological patients’ lives are greatly affected by their disease and treatment. This highlights the need for development of a new measure of HRQoL and symptoms, specific for the assessment of patients with HM to evaluate individual intervention strategies in daily clinical practice. This could lead to greater patient engagement in the process of clinical decision-making.
Session topic: E-poster
Keyword(s): Hematological malignancy, Outcome measurement, Quality of life
Abstract: E1447
Type: Eposter Presentation
Background
The impact of haematological malignancies (HM) in patients' lives is not well understood. For some there is a possibility of cure, for others treatment aims at prolonging survival or containing symptoms and complications. We present interim results of a cross-sectional qualitative study in patients with HM.
Aims
The aim of this study was to investigate the impact of a wide range of haematological malignancies and their treatments on patients’ health-related quality of life (HRQoL) and Symptoms.
Methods
Multicentre Ethics approval was obtained from the NRES South West Bristols, UK. Adult patients with HM as per 2008 WHO classification, capable of reading English and able to give the written informed consent were recruited from inpatient/outpatient clinics of two secondary care hospitals in England and Wales. This qualitative study employed semi-structured face-to-face interviews with open-ended questions related to HRQoL and symptoms. All the interviews were audio recorded and transcribed verbatim and content analysis was carried out using the NVivo 11 qualitative analysis software.
Results
Fifty-five patients (male=27; mean age = 60 years; SD=15.2; median age 63 years; and age range =21-83 years) with mean duration of the HM of 3.8 years (SD=4.7; median=2.1 years; and range= 19 days-23 years) were recruited into the study. Diagnoses were Acute Myeloid Leukaemia (11), Acute Lymphoid Leukaemia (3), Chronic Myeloid Leukaemia (6), Chronic Lymphoid Leukaemia (4), Aggressive Non-Hodgkin’s Lymphoma (3), Indolent Non-Hodgkin’s Lymphoma (7), Hodgkin’s Lymphoma (3), Multiple Myeloma (12), Myeloproliferative Neoplasm (3) and Myelodysplastic Syndrome (3). There were overall 44 categories of issues identified which were important from the patient perspective. These issues were then divided into two broad categories: QoL and symptoms. The QoL issues which had the highest impact on patients’ lives (Figure1) were: ‘social life and participatory function; going on holidays and travelling; physical functioning or independency; sleeping patterns; eating and drinking habits; work life; and sexual life’ from high to low prevalence, respectively. Forty-four percent of the patients experienced impairment in different aspects of their work life with the prevalence of sixty-two percent (4 job role function; 2 made redundant; 3 relationship with co-workers; and 24 overall work life). Most of the patients who suffered from financial difficulties because of their HM were from 35-65 age group. With respect to disease related symptoms, 62 issues were identified, the most prevalent being ‘tiredness (35%), feeling unwell (24%), breathlessness (23%), lack of energy (16%), back pain (15%) and weight loss (13%)', from high to low prevalence respectively. Out of 78 treatment related symptoms identified, the most prevalent symptoms were ‘tiredness (36%), feeling sick (17%), breathlessness (14%), loss of appetite (9%), neutropenia related symptoms such as infections & slowed healing (8%), nausea (8%) and lack of energy (8%)’, from high to low prevalence, respectively.
Conclusion
The findings of this study clearly indicate that haematological patients’ lives are greatly affected by their disease and treatment. This highlights the need for development of a new measure of HRQoL and symptoms, specific for the assessment of patients with HM to evaluate individual intervention strategies in daily clinical practice. This could lead to greater patient engagement in the process of clinical decision-making.
Session topic: E-poster
Keyword(s): Hematological malignancy, Outcome measurement, Quality of life
Type: Eposter Presentation
Background
The impact of haematological malignancies (HM) in patients' lives is not well understood. For some there is a possibility of cure, for others treatment aims at prolonging survival or containing symptoms and complications. We present interim results of a cross-sectional qualitative study in patients with HM.
Aims
The aim of this study was to investigate the impact of a wide range of haematological malignancies and their treatments on patients’ health-related quality of life (HRQoL) and Symptoms.
Methods
Multicentre Ethics approval was obtained from the NRES South West Bristols, UK. Adult patients with HM as per 2008 WHO classification, capable of reading English and able to give the written informed consent were recruited from inpatient/outpatient clinics of two secondary care hospitals in England and Wales. This qualitative study employed semi-structured face-to-face interviews with open-ended questions related to HRQoL and symptoms. All the interviews were audio recorded and transcribed verbatim and content analysis was carried out using the NVivo 11 qualitative analysis software.
Results
Fifty-five patients (male=27; mean age = 60 years; SD=15.2; median age 63 years; and age range =21-83 years) with mean duration of the HM of 3.8 years (SD=4.7; median=2.1 years; and range= 19 days-23 years) were recruited into the study. Diagnoses were Acute Myeloid Leukaemia (11), Acute Lymphoid Leukaemia (3), Chronic Myeloid Leukaemia (6), Chronic Lymphoid Leukaemia (4), Aggressive Non-Hodgkin’s Lymphoma (3), Indolent Non-Hodgkin’s Lymphoma (7), Hodgkin’s Lymphoma (3), Multiple Myeloma (12), Myeloproliferative Neoplasm (3) and Myelodysplastic Syndrome (3). There were overall 44 categories of issues identified which were important from the patient perspective. These issues were then divided into two broad categories: QoL and symptoms. The QoL issues which had the highest impact on patients’ lives (Figure1) were: ‘social life and participatory function; going on holidays and travelling; physical functioning or independency; sleeping patterns; eating and drinking habits; work life; and sexual life’ from high to low prevalence, respectively. Forty-four percent of the patients experienced impairment in different aspects of their work life with the prevalence of sixty-two percent (4 job role function; 2 made redundant; 3 relationship with co-workers; and 24 overall work life). Most of the patients who suffered from financial difficulties because of their HM were from 35-65 age group. With respect to disease related symptoms, 62 issues were identified, the most prevalent being ‘tiredness (35%), feeling unwell (24%), breathlessness (23%), lack of energy (16%), back pain (15%) and weight loss (13%)', from high to low prevalence respectively. Out of 78 treatment related symptoms identified, the most prevalent symptoms were ‘tiredness (36%), feeling sick (17%), breathlessness (14%), loss of appetite (9%), neutropenia related symptoms such as infections & slowed healing (8%), nausea (8%) and lack of energy (8%)’, from high to low prevalence, respectively.
Conclusion
The findings of this study clearly indicate that haematological patients’ lives are greatly affected by their disease and treatment. This highlights the need for development of a new measure of HRQoL and symptoms, specific for the assessment of patients with HM to evaluate individual intervention strategies in daily clinical practice. This could lead to greater patient engagement in the process of clinical decision-making.
Session topic: E-poster
Keyword(s): Hematological malignancy, Outcome measurement, Quality of life
{{ help_message }}
{{filter}}